F16.950 Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with delusions

Name of the Condition

• Hallucinogen Use, Unspecified with Hallucinogen-Induced Psychotic Disorder with Delusions
• Medical Term: ICD-10-CM F16.950

Summary

Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with delusions refers to the use of hallucinogenic substances associated with the development of a psychotic disorder characterized by delusions. This code is applied when clinical documentation confirms hallucinogen exposure and the presence of psychotic symptoms, specifically delusions, without further specification of the use pattern. It encompasses cases where hallucinogen use is linked to persistent or transient delusional thinking, distinct from other psychotic features like hallucinations alone.

Causes

Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with delusions typically involves substances that alter perception, mood, or cognitive function, such as LSD, psilocybin, or mescaline. The psychotic disorder arises from the direct effects of the hallucinogen on the central nervous system, leading to delusional thinking. The documentation does not specify a problematic pattern beyond the association with the induced psychotic disorder with delusions.

Risk Factors

• Recreational or experimental use of hallucinogens
• Pre-existing mental health conditions (e.g., schizophrenia, bipolar disorder)
• Genetic predisposition to psychotic disorders
• High-dose or frequent hallucinogen use
• History of trauma or stress

Symptoms

• Persistent or transient delusions (fixed false beliefs)
• Altered sensory perceptions (e.g., visual or auditory hallucinations)
• Distorted sense of reality or time
• Mood changes, including paranoia or anxiety
• Impaired judgment or decision-making
• Social or occupational dysfunction

Diagnosis

Diagnosis requires clinical documentation of hallucinogen use and the presence of delusions, confirmed by a mental health evaluation. The psychotic symptoms must be directly attributable to hallucinogen exposure, with no other medical or psychiatric causes. Assessment may include psychiatric history, substance use history, and ruling out other conditions (e.g., schizophrenia, mood disorders) that could explain the symptoms.

Treatment Options

Treatment focuses on managing psychotic symptoms and addressing substance use. Antipsychotic medications may be used to reduce delusions. Psychotherapy, including cognitive-behavioral therapy, can help address substance use and coping strategies. Supportive care, such as monitoring for safety and providing education, is often necessary. Inpatient care may be required for severe cases or when there is a risk of harm.

Prognosis and Follow-Up

Prognosis varies depending on the severity of symptoms, duration of use, and response to treatment. Some individuals may experience symptom resolution with abstinence and treatment, while others may have persistent symptoms. Regular follow-up with a mental health provider is essential to monitor symptoms, adjust treatment, and support recovery. Long-term outcomes depend on adherence to treatment and avoidance of hallucinogens.

Complications

• Persistent psychotic symptoms
• Worsening of pre-existing mental health conditions
• Social isolation or relationship difficulties
• Occupational or academic impairment
• Increased risk of self-harm or harm to others
• Legal or financial problems related to substance use

Lifestyle & Prevention

• Avoiding hallucinogenic substances is the primary prevention strategy.
• Engaging in healthy coping mechanisms, such as exercise or mindfulness, to manage stress.
• Building a strong support network of family, friends, or support groups.
• Seeking early intervention for substance use or mental health concerns.
• Educating oneself about the risks of hallucinogen use.

When to Seek Professional Help

Seek professional help if you or someone you know experiences persistent delusions, hallucinations, or other psychotic symptoms after hallucinogen use. Immediate care is needed if there is a risk of self-harm, harm to others, or severe impairment in daily functioning. A mental health provider can assess symptoms and recommend appropriate treatment.

Tips for Medical Coders

When coding F16.950, ensure clinical documentation confirms hallucinogen use and the presence of delusions as part of a hallucinogen-induced psychotic disorder. The code requires specificity in documenting the psychotic feature (delusions) and the association with hallucinogen exposure. Avoid using this code if the psychotic disorder is due to another cause or if the use pattern is specified (e.g., abuse, dependence). Verify that the documentation supports the diagnosis before applying the code.